The amplification of MYCN gene is the most frequent genomic alteration in neuroblastoma, in association with poor cell differentiation and bad prognosis, which occurs in about 25% of primary neuroblastoma tumors and constitutes the major hallmark of high-risk neuroblastoma (Huang and Weiss, 2013; Tolbert and Matthay, 2018; Westermark et al., 2011). Here, MYCN is linked to neuroblastoma.